EXACT Sciences Co. (EXAS) Insider Graham Peter Lidgard Sells 37,613 Shares

EXACT Sciences Co. (NASDAQ:EXAS) insider Graham Peter Lidgard sold 37,613 shares of the stock in a transaction dated Monday, November 5th. The shares were sold at an average price of $75.01, for a total transaction of $2,821,351.13. Following the transaction, the insider now directly owns 29,398 shares of the company’s stock, valued at approximately $2,205,143.98. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Graham Peter Lidgard also recently made the following trade(s):

  • On Wednesday, November 7th, Graham Peter Lidgard sold 38,311 shares of EXACT Sciences stock. The shares were sold at an average price of $75.01, for a total transaction of $2,873,708.11.
  • On Thursday, November 1st, Graham Peter Lidgard sold 79,673 shares of EXACT Sciences stock. The shares were sold at an average price of $71.73, for a total transaction of $5,714,944.29.
  • On Monday, October 8th, Graham Peter Lidgard sold 58,000 shares of EXACT Sciences stock. The shares were sold at an average price of $69.36, for a total transaction of $4,022,880.00.

EXACT Sciences stock traded up $2.53 during midday trading on Thursday, reaching $78.01. The stock had a trading volume of 43,050 shares, compared to its average volume of 2,173,873. The company has a debt-to-equity ratio of 0.94, a current ratio of 12.08 and a quick ratio of 11.72. EXACT Sciences Co. has a 52-week low of $37.36 and a 52-week high of $81.22. The firm has a market capitalization of $9.12 billion, a P/E ratio of -78.80 and a beta of 1.21.

EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Tuesday, October 30th. The medical research company reported ($0.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.05. EXACT Sciences had a negative net margin of 35.83% and a negative return on equity of 20.18%. The company had revenue of $118.29 million for the quarter, compared to analyst estimates of $109.33 million. During the same period in the prior year, the company posted ($0.23) EPS. The firm’s revenue for the quarter was up 63.0% on a year-over-year basis. Research analysts anticipate that EXACT Sciences Co. will post -1.53 earnings per share for the current fiscal year.

Several research analysts have commented on the stock. Zacks Investment Research downgraded shares of EXACT Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, October 23rd. BidaskClub raised shares of EXACT Sciences from a “sell” rating to a “hold” rating in a report on Friday, November 2nd. Jefferies Financial Group lowered their price target on shares of EXACT Sciences from $60.00 to $57.00 and set a “buy” rating for the company in a report on Thursday, August 2nd. Leerink Swann reaffirmed an “outperform” rating and issued a $76.00 price target (up previously from $67.00) on shares of EXACT Sciences in a report on Wednesday, July 18th. Finally, UBS Group set a $100.00 price target on shares of EXACT Sciences and gave the company a “buy” rating in a report on Tuesday, October 30th. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. EXACT Sciences presently has a consensus rating of “Buy” and a consensus price target of $84.08.

Institutional investors have recently bought and sold shares of the stock. KAMES CAPITAL plc purchased a new position in shares of EXACT Sciences during the second quarter worth approximately $46,879,000. First Trust Advisors LP increased its holdings in EXACT Sciences by 6,220.7% during the third quarter. First Trust Advisors LP now owns 524,744 shares of the medical research company’s stock valued at $41,413,000 after buying an additional 516,442 shares during the period. CIBC Private Wealth Group LLC increased its holdings in EXACT Sciences by 76.9% during the second quarter. CIBC Private Wealth Group LLC now owns 1,107,136 shares of the medical research company’s stock valued at $66,196,000 after buying an additional 481,230 shares during the period. Frontier Capital Management Co. LLC increased its holdings in EXACT Sciences by 37.7% during the third quarter. Frontier Capital Management Co. LLC now owns 1,585,851 shares of the medical research company’s stock valued at $125,155,000 after buying an additional 434,184 shares during the period. Finally, Artisan Partners Limited Partnership increased its holdings in EXACT Sciences by 25.8% during the second quarter. Artisan Partners Limited Partnership now owns 1,879,525 shares of the medical research company’s stock valued at $112,377,000 after buying an additional 385,766 shares during the period. 87.06% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “EXACT Sciences Co. (EXAS) Insider Graham Peter Lidgard Sells 37,613 Shares” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.themarketsdaily.com/2018/11/08/exact-sciences-co-exas-insider-graham-peter-lidgard-sells-37613-shares.html.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Read More: Diversification

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply